间变性淋巴瘤激酶
淋巴瘤
浆母细胞性淋巴瘤
免疫分型
癌症研究
间变性大细胞淋巴瘤
医学
恶性肿瘤
抗原
病理
免疫学
恶性胸腔积液
肺癌
作者
Jian Jeff Fu,Anjali Seth,Nadia Ali,Ashwin Chandar,Ashish Bains
标识
DOI:10.1097/pas.0000000000002069
摘要
Anaplastic lymphoma kinase (ALK)-positive large B-cell lymphoma (LBCL) is a very rare type of LBCL with an aggressive clinical course and poor prognosis. This diagnosis can be challenging given the varied morphology (immunoblastic, plasmablastic, or anaplastic), frequent lack of B-cell antigens, and especially in cases with expression of epithelial antigens. Here, we report a case of ALK-positive LBCL with unusual expression of 4 epithelial-associated markers (AE1/AE3, CK8/18, EMA, and GATA3) and novel poly(A) binding protein cytoplasmic 1 (PABPC1) :: ALK fusion which has not been previously reported in this entity. This case also emphasizes the use of comprehensive immunophenotyping that includes multiple lineage-specific antibodies when faced with a malignancy without a clear differentiation to avoid misdiagnosis. This case only achieved partial response to combination chemotherapy, radiation, and ALK inhibitor regimens, and furthers our understanding of this uncommon lymphoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI